title: Androgen suppression plus radiation versus radiation alone for patients with D1 (pN+) adenocarcinoma of the prostate (results based on a national prospective randomized trial, RTOG 85-31). Radiation Therapy Oncology Group.
abstract: OBJECTIVE
  To evaluate the effect of immediate androgen suppression in conjunction with standard external beam irradiation vs. radiation alone on a group of pathologically staged lymph node-positive patients with adenocarcinoma of the prostate.
  
  
  METHODS
  A national prospective randomized trial (RTOG 85-31) of standard external beam irradiation plus immediate androgen suppression vs. external beam irradiation alone was initiated in 1985 for patients with locally advanced adenocarcinoma of the prostate. One hundred seventy-three of the patients in this trial had biopsy-proven pathologically involved lymph nodes. Ninety-eight of these patients received radiation plus the immediate androgen suppression (LHRH agonist), while 75 received radiation alone with hormonal manipulation instituted at the time of relapse.
  
  
  RESULTS
  With a median followup of 4.9 years, estimated progression-free survival with PSA < 1.5 ng/ml at 5 years was 55% for the patients who received radiation plus immediate LHRH agonist vs. 11% of the patients who received radiation alone with hormonal manipulation at relapse (p = 0.0001). Because all of these patients had locally advanced disease (i.e., pathologically positive lymph nodes), stage does not explain this difference in outcome, and Gleason grade was not statistically different between the two groups. Estimated absolute survival at 5 years for the radiation and LHRH group was 73 vs. 65% for the radiation alone group who received androgen suppression at relapse. Estimated disease-specific survival at 5 years was 82% for the radiation and immediate LHRH agonist group and 77% for the radiation-alone group.
  
  
  CONCLUSIONS
  Patients with adenocarcinoma of the prostate and pathologically involved pelvic lymph nodes (pN+ or clinical stage D1) should be seriously considered for external beam irradiation plus immediate hormonal manipulation over radiation alone with hormonal manipulation at the time of relapse.
authors.affiliation: Medical College of Wisconsin, Radiation Oncology, Milwaukee 53226, USA.
authors.forename: C A
authors.initials: CA
authors.lastname: Lawton
authors.forename: K
authors.initials: K
authors.lastname: Winter
authors.forename: R
authors.initials: R
authors.lastname: Byhardt
authors.forename: W T
authors.initials: WT
authors.lastname: Sause
authors.forename: G E
authors.initials: GE
authors.lastname: Hanks
authors.forename: A H
authors.initials: AH
authors.lastname: Russell
authors.forename: M
authors.initials: M
authors.lastname: Rotman
authors.forename: A
authors.initials: A
authors.lastname: Porter
authors.forename: D G
authors.initials: DG
authors.lastname: McGowan
authors.forename: J D
authors.initials: JD
authors.lastname: DelRowe
authors.forename: M V
authors.initials: MV
authors.lastname: Pilepich
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology / Q000532:radiotherapy / Q000628:therapy*; D000328:Adult; D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005500:Follow-Up Studies; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D010388:Pelvis; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000473:pathology / Q000532:radiotherapy / Q000628:therapy*
chemical_list: D000726:Androgen Antagonists; D007987:Gonadotropin-Releasing Hormone